Adamis Pharmaceuticals Corporation (ADMP)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7307 |
| Open | 0.7300 |
| Bid | 0.6860 x 1200 |
| Ask | 0.6699 x 900 |
| Day's Range | 0.6615 - 0.7399 |
| 52 Week Range | 0.4700 - 2.3400 |
| Volume | |
| Avg. Volume | 6,131,792 |
| Market Cap | 101.51M |
| Beta (5Y Monthly) | 1.32 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6370 |
| Earnings Date | Nov 08, 2021 - Nov 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
Drug overdoses are the leading cause of death for those under age 50SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of naloxone hydrochloride that is included in the company’s ZIMHI™ (naloxone HCL Injection, USP) 5 mg/0.5 mL product. The model data supports the dose of naloxone in ZIMHI as being more likely to produce successful resuscitation of high
- GlobeNewswire
Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“NASDAQ”) notifying the company that based on the company’s filing of its Quarterly Reports on Form 10-Q for the periods ended March 31,
- GlobeNewswire
Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2 p.m. PT / 5 p.m. ETSAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid overdose, respiratory and inflammatory disease, today announced financial results for the nine months ended September 30, 2021 and provided a business update. “Adamis made significant advancements over the past year,” stated Dennis J
